*ST赛隆子公司取得两项化学原料药上市申请批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing authorization of magnesium aspartate and potassium aspartate as chemical raw materials, which are essential for producing electrolyte replenishment medications [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has obtained the marketing authorization approval for magnesium aspartate and potassium aspartate [1] - The approved chemical raw materials can be used to produce potassium aspartate injection and magnesium aspartate injection formulations [1] Group 2: Industry Implications - Magnesium aspartate and potassium aspartate are classified as electrolyte replenishment drugs, indicating their importance in the pharmaceutical industry for treating electrolyte imbalances [1]